Status:
RECRUITING
CXCR4-targeted PET/CT Imaging in Hematological Malignancies
Lead Sponsor:
Zhongnan Hospital
Conditions:
CXCR4
PET/CT
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Hematological malignancies continue to pose significant clinical challenges due to their high incidence, heterogeneous biology, and substantial mortality. Although 18F-FDG PET/CT remains the most comm...
Detailed Description
Hematological malignancies encompass a heterogeneous group of neoplasms originating from the bone marrow and lymphatic system. Despite advances in therapeutic strategies, the prognosis for many subtyp...
Eligibility Criteria
Inclusion
- Volunteer to participate and sign an informed consent form;
- 18 ≤ Age ≤ 90 years;
- Patients with highly suspected, or newly diagnosed, or relapsed hematological malignancies;
- Willing and able to follow schedule visits, treatment plans and laboratory tests.
Exclusion
- pregnancy or breastfeeding;
- Allergic to CXCR4-targeted tracers or excipients;
- Fasting blood glucose level exceeded 11.0 mmol/L prior to injection of 18F-FDG;
- Those who cannot complete PET/CT scan, including inability to keep supine, claustrophobia, radiation phobia, etc.;
- Researchers think it is inappropriate to participate in this clinical trial for patients with poor compliance or other unsuitable factors.
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05255926
Start Date
March 1 2022
End Date
December 31 2026
Last Update
June 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430071